0.4391
price up icon2.76%   0.0118
after-market After Hours: .45 0.0109 +2.48%
loading
Bioline Rx Ltd Adr stock is traded at $0.4391, with a volume of 563.68K. It is up +2.76% in the last 24 hours and down -4.54% over the past month. BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
See More
Previous Close:
$0.4273
Open:
$0.42
24h Volume:
563.68K
Relative Volume:
1.93
Market Cap:
$36.05M
Revenue:
-
Net Income/Loss:
$-60.61M
P/E Ratio:
-0.7318
EPS:
-0.6
Net Cash Flow:
$-22.91M
1W Performance:
+1.06%
1M Performance:
-4.54%
6M Performance:
-35.43%
1Y Performance:
-73.06%
1-Day Range:
Value
$0.42
$0.4699
1-Week Range:
Value
$0.397
$0.4699
52-Week Range:
Value
$0.39
$1.93

Bioline Rx Ltd Adr Stock (BLRX) Company Profile

Name
Name
Bioline Rx Ltd Adr
Name
Phone
-
Name
Address
-
Name
Employee
79
Name
Twitter
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
BLRX's Discussions on Twitter

Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-18-17 Upgrade Maxim Group Hold → Buy
Feb-13-17 Initiated Rodman & Renshaw Buy
Aug-12-16 Downgrade Maxim Group Buy → Hold
Aug-17-15 Reiterated Maxim Group Buy
Jul-27-15 Reiterated ROTH Capital Buy
Jun-22-15 Initiated JMP Securities Mkt Outperform
View All

Bioline Rx Ltd Adr Stock (BLRX) Latest News

pulisher
09:31 AM

BioLineRx’s Motixafortide Shows Promise in Sickle Cell Trials - TipRanks

09:31 AM
pulisher
Oct 24, 2024

BioLineRx stock hits 52-week low at $0.39 amid market challenges - Investing.com India

Oct 24, 2024
pulisher
Oct 16, 2024

BioLineRx Secures Extended U.S. Patent for Motixafortide - TipRanks

Oct 16, 2024
pulisher
Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

BioLineRx secures US patent for cancer drug motixafortide By Investing.com - Investing.com UK

Oct 16, 2024
pulisher
Oct 15, 2024

BioLineRx stock hits 52-week low at $0.43 amid market challenges - Investing.com

Oct 15, 2024
pulisher
Oct 07, 2024

Riding the Waves: A Guide to Investing in BLRX Stock - The InvestChronicle

Oct 07, 2024
pulisher
Oct 07, 2024

Market Insight: Bioline Rx Ltd ADR (BLRX)’s Notable Drop, Closing at 0.46 - The Dwinnex

Oct 07, 2024
pulisher
Oct 02, 2024

BioLineRx stock hits 52-week low at $0.5 amid market challenges - Investing.com

Oct 02, 2024
pulisher
Oct 01, 2024

BioLineRx Ltd. Shareholders Approve Key Resolutions - TipRanks

Oct 01, 2024
pulisher
Oct 01, 2024

Bioline Rx Ltd ADR (BLRX) Stock: A Year of Market Fluctuations - The InvestChronicle

Oct 01, 2024
pulisher
Oct 01, 2024

Stock Market Recap: Bioline Rx Ltd ADR (BLRX) Concludes at 0.54, a -13.53 Surge/Decline - The Dwinnex

Oct 01, 2024
pulisher
Sep 02, 2024

A new trading data show Bioline Rx Ltd ADR (BLRX) is showing positive returns. - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

Metric Analysis: Bioline Rx Ltd ADR (BLRX)’s Key Ratios in the Limelight - The Dwinnex

Sep 02, 2024
pulisher
Sep 02, 2024

BLRX overperforms with a 0.95 increase in share price - US Post News

Sep 02, 2024
pulisher
Aug 19, 2024

BioLineRx Schedules Annual Shareholders Meeting - TipRanks

Aug 19, 2024
pulisher
Aug 16, 2024

Financial Analysis: Bioline Rx Ltd ADR (BLRX)’s Ratios Unveil Key Insights - The Dwinnex

Aug 16, 2024
pulisher
Aug 16, 2024

BLRX Stock: Exploring Bioline Rx Ltd ADR’s Growth - The InvestChronicle

Aug 16, 2024
pulisher
Aug 16, 2024

Earnings call: BioLineRx beats Q2 goals with strong APHEXDA demand - Investing.com

Aug 16, 2024
pulisher
Aug 15, 2024

BioLineRx’s Strong Quarter with APHEXDA Growth - TipRanks

Aug 15, 2024
pulisher
Aug 15, 2024

Options Volatility and Implied Earnings Moves Today, August 15, 2024 - TipRanks

Aug 15, 2024
pulisher
Jul 30, 2024

Bioline Rx Ltd ADR’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - The InvestChronicle

Jul 30, 2024
pulisher
Jul 30, 2024

Ratio Revelations: Bioline Rx Ltd ADR (BLRX)’s Financial Metrics in the Spotlight - The Dwinnex

Jul 30, 2024
pulisher
Jul 18, 2024

There is no doubt that Bioline Rx Ltd ADR (BLRX) ticks all the boxes. - SETE News

Jul 18, 2024
pulisher
Jul 17, 2024

Bioline Rx Ltd ADR (BLRX) stock analysis: A simple moving average approach - US Post News

Jul 17, 2024
pulisher
Jul 11, 2024

BLRX’s Stock Journey: What Investors Need to Know About Bioline Rx Ltd ADR’s Performance - The InvestChronicle

Jul 11, 2024
pulisher
Jul 04, 2024

Financial Analysis: Bioline Rx Ltd ADR (BLRX)'s Ratios Unveil Key Insights – DWinneX - The Dwinnex

Jul 04, 2024
pulisher
Jun 19, 2024

Bioline Rx Ltd ADR Inc. (BLRX) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle

Jun 19, 2024
pulisher
Jun 14, 2024

BLRXBioLineRx Reports Second Quarter 2011 Financial Results - br.ADVFN.com

Jun 14, 2024
pulisher
Jun 01, 2024

What Can Bioline Rx Ltd ADR (NASDAQ: BLRX) Expect In 2024? – Stocks Register - Stocks Register

Jun 01, 2024
pulisher
May 31, 2024

Bioline Rx Ltd ADR (BLRX) stock: A year of ups and downs – US Post News - US Post News

May 31, 2024
pulisher
May 30, 2024

Bioline Rx Ltd ADR (BLRX)'s Market Momentum: Closing Strong at 0.69, Down -4.03 – DWinneX - The Dwinnex

May 30, 2024
pulisher
May 30, 2024

BioLineRx Trials New Sickle Cell Gene Therapy - TipRanks

May 30, 2024
pulisher
May 30, 2024

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applicatio - Investing.com India

May 30, 2024
pulisher
May 29, 2024

Understanding the Risks of Investing in Bioline Rx Ltd ADR (BLRX) – Knox Daily - Knox Daily

May 29, 2024
pulisher
May 29, 2024

Earnings call: BioLineRx Q1 2024 results show steady progress - Investing.com India

May 29, 2024
pulisher
May 29, 2024

Earnings call: BioLineRx Q1 2024 results show steady progress By Investing.com - Investing.com

May 29, 2024
pulisher
May 28, 2024

BioLineRx Q1 Success with APHEXDA® Growth - TipRanks

May 28, 2024
pulisher
May 28, 2024

Bioline Rx Ltd ADR (BLRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle

May 28, 2024
pulisher
May 28, 2024

Are Smart Investors Making the Right Decision? Bioline Rx Ltd ADR (BLRX) – Sete News - SETE News

May 28, 2024
pulisher
May 25, 2024

BioLineRx to present new data from CheMo4METPANC Phase 2 at ASCOTipRanks.com - TipRanks

May 25, 2024
pulisher
May 24, 2024

BioLineRx reports positive pancreatic cancer trial results By Investing.com - Investing.com

May 24, 2024
pulisher
May 24, 2024

Ratios Reveal: Breaking Down Bioline Rx Ltd ADR (BLRX)'s Financial Health – DWinneX - The Dwinnex

May 24, 2024
pulisher
May 24, 2024

Examining Bioline Rx Ltd ADR (BLRX) more closely is necessary – US Post News - US Post News

May 24, 2024
pulisher
May 24, 2024

BioLineRx Showcases Promising Cancer Drug Trial Results - TipRanks

May 24, 2024
pulisher
May 17, 2024

BioLineRx Faces Nasdaq Compliance ChallengeTipRanks.com - TipRanks

May 17, 2024
pulisher
May 17, 2024

BioLineRx faces Nasdaq minimum bid price noncompliance By Investing.com - Investing.com

May 17, 2024
pulisher
May 17, 2024

Market Resilience: Bioline Rx Ltd ADR (BLRX) Finishes Strong/Weak at 0.641, Up 4.04 – DWinneX - The Dwinnex

May 17, 2024
pulisher
May 06, 2024

BioLineRx Reveals Cost-Saving Stem Cell Mobilization DataTipRanks.com - TipRanks

May 06, 2024
pulisher
Apr 17, 2024

BioLineRx Enhances Multiple Myeloma TreatmentTipRanks.com - TipRanks

Apr 17, 2024
pulisher
Apr 10, 2024

BioLineRx secures $20 million in BlackRock financing By Investing.com - Investing.com

Apr 10, 2024

Bioline Rx Ltd Adr Stock (BLRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):